A biotech that closes a round does not spend the money slowly. They spend it in a predictable order, on a predictable timeline, and every vendor category has a window that opens and closes. Knowing the sequence is worth more than knowing the company.
Why the spending is fast
A financing is not a cushion. It is a countdown. The company raised to reach a specific value-inflection milestone, usually a data readout, before the money runs out, and every week of delay eats runway they cannot replace.
So they move. Immediately. And the sequence is remarkably consistent.
The sequence
Weeks 1 to 4: people and plan. Leadership hires get made or accelerated, particularly clinical and regulatory. The development plan gets locked. Recruiters who are in the conversation now are in it.
Weeks 4 to 12: the big vendor decisions. The CRO conversation happens here. Manufacturing gets scoped, because drug supply is on the critical path and long lead times force early decisions. Regulatory strategy support gets engaged, since the path has to be set before the trial is designed.
Weeks 8 to 20: the operational stack. Trial technology, central labs, bioanalysis, specialized services. These follow once the CRO and protocol shape is settled.
Beyond: the doors close. The vendors are chosen, the contracts are signed, and the company is executing. A CRO calling in month seven is not competing, they are being politely filed.
What this means for your outreach
If you sell manufacturing, your window opens almost immediately and closes fast, because lead times force early commitment. If you sell trial technology, calling in week two is premature, because they have not chosen a CRO yet and the CRO may influence the stack. If you recruit, you are already late by week four.
Most vendors call at the same time, when they eventually notice the round. The ones who win call when their specific window is open, which requires knowing both the event and the sequence.
The uncomfortable implication
If you are finding out about funding rounds a month or two after they close, you are systematically arriving after your window has shut, for every prospect, forever. That is not a sales performance problem. It is an information problem, and no amount of coaching fixes it.
Know who to call
Every round that closed this month started a clock. Some of those windows are already closing.
Get Signals for your BD team, $8,000/year for up to 5 seats
Or a single seat, $2,500/year
Every Friday: 15 to 20 tagged signals, a “Who To Call This Week” list of 10 prioritized targets with the trigger and a suggested opening line, and a monthly outreach playbook. Two-week free trial, no commitment. See also the buying signals biotech vendors keep missing.
Frequently asked questions
What do biotechs buy after raising money?
In a fairly consistent sequence: leadership hiring and development planning in the first month, then the big vendor decisions (CRO, manufacturing, regulatory strategy) between roughly weeks four and twelve, then the operational stack (trial technology, central labs, bioanalysis) from weeks eight to twenty. After that the decisions are made.
How long is the window after a biotech funding round?
It varies by vendor category. Manufacturing opens almost immediately and closes fast because lead times force early commitment. Recruiting is often late by week four. CRO decisions typically happen between weeks four and twelve. By month six or seven, most vendor decisions are made and contracts signed.
Why do vendors miss the post-funding window?
Because they find out about the round weeks or months after it closed, by which point their specific window has already shut. This happens systematically, for every prospect, which makes it an information problem rather than a sales performance problem, and no amount of coaching or better templates will fix it.
